Wegovy Alternatives Online in 2026: A Complete Comparison
By GLP-1 Evolution Research Team | Last updated: May 18, 2026
TL;DR
- The strongest Wegovy alternatives in 2026: Zepbound (tirzepatide), compounded semaglutide, compounded tirzepatide.
- SURMOUNT-1 tirzepatide 15 mg: ~22.5% mean weight loss at 72 weeks vs STEP-1 semaglutide 2.4 mg ~14.9% at 68 weeks.
- Compounded options reduce monthly cost from $1,000-$1,400 to $129-$349.
- Saxenda (daily liraglutide) remains an alternative but produces smaller losses.
- Retatrutide is investigational and not yet available through any legitimate program.
Why Patients Look for Alternatives
Three reasons dominate the search for Wegovy alternatives: cost (most insurance won't cover the obesity indication), supply (intermittent shortages in 2024-2025 trained patients to have a backup), and effectiveness (some patients want the larger weight-loss potential of tirzepatide). Each alternative below addresses one or more of these.
Alternative 1: Zepbound (Tirzepatide)
Zepbound is Eli Lilly's tirzepatide branded for chronic weight management (FDA-approved November 2023). Same molecule as Mounjaro. In SURMOUNT-1 (Jastreboff et al., NEJM 2022, PMID 35658024), tirzepatide 15 mg produced about 22.5% mean weight loss at 72 weeks. Retail pricing is comparable to Wegovy ($1,000-$1,400/month). Lilly Direct sells self-pay vials at a lower price point. For most patients seeking a branded alternative with stronger weight-loss data, Zepbound is the answer.
Alternative 2: Compounded Semaglutide
Same molecule as Wegovy, prepared by a 503A or 503B compounding pharmacy. Cost: $129-$249/month via vetted telehealth. The trade-offs are explained in our compounded GLP-1 buyer's guide. For patients who want Wegovy's mechanism at a fraction of the price, this is the most common path in 2026.
Alternative 3: Compounded Tirzepatide
Compounded tirzepatide combines the higher efficacy of SURMOUNT-1 with cash-pay accessibility. Typical price range: $179-$349/month. Available through several US-licensed telehealth programs including Embody, Eden Health, and SHED.
Alternative 4: Saxenda (Liraglutide)
Saxenda is daily injectable liraglutide, the predecessor to semaglutide. Mean weight loss in clinical trials was approximately 5-8% — smaller than semaglutide or tirzepatide. Some insurance plans cover Saxenda when newer GLP-1s aren't covered. Daily injection is a downside for most patients.
Alternative 5: Off-Label Mounjaro
Mounjaro is tirzepatide approved for type 2 diabetes. Prescribing it off-label for weight loss is legal but insurance won't cover off-label use. With Zepbound now available, off-label Mounjaro for weight loss is less common in 2026.
Investigational: Retatrutide
Retatrutide is Eli Lilly's triple agonist (GLP-1 + GIP + glucagon). Phase 2 data (Jastreboff et al., NEJM 2023, PMID 37296141) suggested mean weight loss up to 24.2% at 48 weeks. Phase 3 (TRIUMPH program) is ongoing. Retatrutide is not FDA-approved as of 2026. Any program claiming to prescribe retatrutide outside a clinical trial is operating outside the law. See our retatrutide approval timeline for the latest.
How to Decide
- If insurance covers Wegovy: stay on Wegovy.
- If insurance covers Zepbound: Zepbound is generally the higher-efficacy choice.
- If paying cash and you want maximum weight loss: compounded tirzepatide.
- If paying cash and you want lowest cost: compounded semaglutide at $129-$199/month.
- If you don't tolerate injections: ask about Embody's GLP-1 gum format.
Frequently Asked Questions
Main alternatives to Wegovy?
Zepbound, compounded semaglutide, compounded tirzepatide, Saxenda, off-label Mounjaro.
Tirzepatide more effective than semaglutide?
Yes in head-to-head SURMOUNT-5 and based on separate trial averages.
Cheapest alternative?
Compounded semaglutide ~$129/month entry.
Can I switch from Wegovy to compounded?
Yes — your prescriber can transition you without restarting escalation.
Is Saxenda still relevant?
For some patients with specific insurance coverage; smaller weight loss than weekly agents.
Off-label Mounjaro allowed?
Yes legally; insurance won't cover.
What about retatrutide?
Investigational, not FDA-approved, not legally available outside trials.